Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
Hello. Sign In
Your Account

Log In to ComplianceOnline
Welcome back! Please log in below to continue.
0
Cart
Toll Free:
+1-888-717-2436
+1-888-717-2436
Industries
- Banking & Financial Services
- BANKING & FINANCIAL SERVICES
- Banks and Credit Unions
- Financial Services and Trading
- Insurance
- Accounting and Taxation
- Life Sciences
- Hitech, Aero & Manufacturing
- HITECH, AERO & MANUFACTURING
- Quality & Safety
- Standards and Methodology
- Energy & Utilities
- ENERGY & UTILITIES
- IT Security
- Reliability (NERC / FERC)
- Quality and Safety
- Risk Management
- CPG & Retail
- CPG & RETAIL
- Retail Audit
- Quality & Safety
- Social Compliance
- Healthcare
- Food & Dietary Supplements
- Cross Industry Functions
Webinars
By Industries
Seminars
Quality Control Laboratory Compliance - cGMPs and GLPs
Process Validation Guidance Requirements (FDA and EU Annex 15: ...
FDA Recalls - Before You Start, and After You Finish
Biostatistics for the Non-Statistician
Data Integrity: FDA/EU Requirements and Implementation
Managing Domestic and Foreign FDA Inspections and the ...
Recordkeeping and Documentation in a GLP Laboratory ...
Reduce costs for compliance with data integrity: 21 CFR Part 11 ...
Change Control Best Practices - Avoiding Unintended ...
Technical Writing for Pharma, Biotech and Medical Devices
Standards
Aerospace
Agriculture and Farm Machinery
Automotive, Aircraft & Marine technology
Banking, Corp. finance & Sox
Biotech & Pharmaceutical Standards
Chemical technology
Civil engineering and construction
Computer Hardware
Electrical Engineering
Electronic Equipment
ANSI
Audit Net
BIN
BPA
Business Basics
Complianceonline
IT Governance
LabCompliance
Quality-Control-Plan
RCGLOBAL
SHOQ Quality Assurance Manuals
SEPT
Home
› Best Practices
FDA tells Invisalign Maker to Report Side Effects
- Date: December 09, 2010
- Source: Admin
The FDA has issued a warning letter to Align Technology Inc., a company that makes a popular teeth straightener, the Invisalign system, on its failure to report information about patient side effects. The warning letter accused the company of failing to comply with FDA requirements to report serious side effects associated with medical devices. It cited some patient complaints about allergic reactions to the Invisalign trays such as swollen lips and mouth ulcers.
Align Technology's general counsel, Roger George admitted that the company had received a warning letter from the FDA on Nov 18 following an inspection and that it had replied to the FDA on Nov 22. It is working to resolve the issue.
FDA regulations on medical devices
Medical device compliance activities promote and protect public health by ensuring the safety and effectiveness of medical devices through enforcement of the Federal Food, Drug, and Cosmetic Act. The devices are classified as follows:
Align Technology's general counsel, Roger George admitted that the company had received a warning letter from the FDA on Nov 18 following an inspection and that it had replied to the FDA on Nov 22. It is working to resolve the issue.
FDA regulations on medical devices
Medical device compliance activities promote and protect public health by ensuring the safety and effectiveness of medical devices through enforcement of the Federal Food, Drug, and Cosmetic Act. The devices are classified as follows:
- Class I devices are defined as non-life sustaining. These products are the least complicated and their failure poses little risk.
- Class II devices are more complicated and present more risk than Class I devices, though they are also non-life sustaining. They are also subject to any specific performance standards.
- Class III devices sustain or support life, so their failure is life-threatening.
A medical device can be marketed in USA only after submitting a marketing application to the FDA and receiving its approval. All medical devices must be manufactured under a quality assurance program, be suitable for the intended use, be adequately packaged and properly labeled, and have establishment registration and device listing forms on file with the FDA.
FDA Action
In 2004, FDA sought an injunction against Utah Medical Products, Inc. (Utah Medical), of Midvale, Utah. The government took this action after a series of FDA inspections over three years revealed a pattern of significant deviations from the Quality System regulation at Utah Medical's Midvale facility. Despite repeated warnings from the FDA, including a warning letter following one of the inspections, Utah Medical had consistently failed to ensure that its products were manufactured in accordance with the Quality System regulation. Subsequently the government's complaint was filed by the U.S Department of Justice in the District Court of Utah. Thereafter the manufacture and distribution of medical devices by the company was banned until the firm could demonstrate a correction in the deviations from CGMP (Current Good Manufacturing Practices).
FDA Action
In 2004, FDA sought an injunction against Utah Medical Products, Inc. (Utah Medical), of Midvale, Utah. The government took this action after a series of FDA inspections over three years revealed a pattern of significant deviations from the Quality System regulation at Utah Medical's Midvale facility. Despite repeated warnings from the FDA, including a warning letter following one of the inspections, Utah Medical had consistently failed to ensure that its products were manufactured in accordance with the Quality System regulation. Subsequently the government's complaint was filed by the U.S Department of Justice in the District Court of Utah. Thereafter the manufacture and distribution of medical devices by the company was banned until the firm could demonstrate a correction in the deviations from CGMP (Current Good Manufacturing Practices).
Source:
Compliance Trainings

Pregnancy in the Workplace: Strategies to Protect Your Organization from Pregnancy Discrimination Claims
By - Christopher W. Olmsted
On Demand Access Anytime
By - Christopher W. Olmsted
On Demand Access Anytime

How to Vet an IRB: Expose and Fix Problems Before They Threaten Your Trial
By - Madhavi Diwanji
On Demand Access Anytime
By - Madhavi Diwanji
On Demand Access Anytime

Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $249
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
San Francisco, CA | Aug 6-7, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 18-19, 2020
-
Los Angeles, CA | Aug 20-21, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 25-26, 2020
-
Virtual Seminar | Jun 10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | Jul 6-7, 2020
-
San Francisco, CA | Oct 22-23, 2020
-
Virtual Seminar | Jul 9-10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | June 3-4, 2020
-
Miami, FL | Jul 29-31, 2020
-
Virtual Seminar | Jun 17, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed
